Skip to main content
Access Resources

MJFF Publications

1711 - 1720 of 7540 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • RESTRICTED
    Title: Physician‐Assisted Dying: Access and Utilization in Patients with Movement Disorders
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.28964
    Best OA location URL:
    Citation Count: 2
  • RESTRICTED
    Title: Validation of the Arabic Version of the Movement Disorder Society‐Unified Parkinson's Disease Rating Scale
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.28905
    Best OA location URL:
    Citation Count: 2
  • RESTRICTED
    Title: CSF and Serum Levels of Inflammatory Markers in PD: Sparse Correlation, Sex Differences and Association With Neurodegenerative Biomarkers
    Journal Name: Frontiers in Neurology
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fneur.2022.834580
    Citation Count: 16
  • RESTRICTED
    Title: Etiology, pathological characteristics, and clinical management of black pleural effusion
    Journal Name: Medicine
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.1097/md.0000000000028130
    Citation Count: 6
  • RESTRICTED
    Title: Nanobodies as allosteric modulators of Parkinson’s disease–associated LRRK2
    Journal Name: Proceedings of the National Academy of Sciences
    Publisher: Proceedings of the National Academy of Sciences
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1073/pnas.2112712119
    Citation Count: 15
  • RESTRICTED
    Title: Slowing Parkinson’s Disease Progression with Vaccination and Other Immunotherapies
    Journal Name: CNS Drugs
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1007/s40263-022-00903-7
    Best OA location URL:
    Citation Count: 6
  • RESTRICTED
    Title: Defining Utility Values for Chorea Health States in Patients with Huntington’s Disease
    Journal Name: Advances in Therapy
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1007/s12325-022-02046-z
    Citation Count: 1
  • RESTRICTED
    Title: Hydrop enables droplet-based single-cell ATAC-seq and single-cell RNA-seq using dissolvable hydrogel beads
    Journal Name: eLife
    Publisher: eLife Sciences Publications, Ltd
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.7554/elife.73971
    Citation Count: 36
  • RESTRICTED
    Title: Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study
    Journal Name: Frontiers in Neurology
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fneur.2022.773999
    Citation Count: 2
  • RESTRICTED
    Title: Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease
    Journal Name: Molecular Neurodegeneration
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1186/s13024-022-00520-4
    Citation Count: 8
Filters
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.